Paradigm Biocapital Advisors LP Immatics N.V. Transaction History
Paradigm Biocapital Advisors LP
- $2.67 Billion
- Q1 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Immatics N.V. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,818,908 shares of IMTX stock, worth $32.8 Million. This represents 1.11% of its overall portfolio holdings.
Number of Shares
2,818,908
Previous 2,136,339
31.95%
Holding current value
$32.8 Million
Previous $22.5 Million
31.7%
% of portfolio
1.11%
Previous 1.17%
Shares
4 transactions
Others Institutions Holding IMTX
# of Institutions
85Shares Held
68.8MCall Options Held
507KPut Options Held
170K-
Rtw Investments, LP New York, NY10MShares$116 Million1.69% of portfolio
-
Wellington Management Group LLP Boston, MA8.33MShares$96.8 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY6.44MShares$74.9 Million0.86% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.3MShares$73.3 Million0.04% of portfolio
-
Perceptive Advisors LLC New York, NY4.58MShares$53.2 Million1.01% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $886M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...